alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<Page>

                                                                    EXHIBIT 99.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of United Stationers Inc. and United
Stationers Supply Co. (collectively, the "Company") on Form 10-K for the year
ended December 31, 2002 as filed with the Securities and Exchange Commission on
the date hereof (the "Report"), I, Kathleen S. Dvorak, Senior Vice President and
Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.

A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.

/s/ Kathleen S. Dvorak
------------------------------------------

Kathleen S. Dvorak
Senior Vice President and Chief Financial Officer
March 28, 2003
§ 520.1289 Lufenuron suspension. ( a ) *Specifications.* Each individual dose pack contains either 135 or 270 milligrams of lufenuron.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cats* — ( 1 ) *Amount.* Minimum of 13.6 milligrams per pound of body weight (30 milligrams per kilogram). Recommended dose of 135 milligrams for up to 10 pounds of body weight or 270 milligrams for 11 to 20 pounds. Cats over 20 pounds are provided the appropriate combination of packs.
( 2 ) *Indications for use.* For control of flea populations.
( 3 ) *Limitations.* For oral use in cats 6 weeks of age or older, once a month, mixed with food. Administer in conjunction with a full meal to ensure adequate absorption. Treat all cats in the household to ensure maximum benefits. Because the drug has no affect on adult fleas, the concurrent use of insecticides that kill adults may be necessary depending on the severity of the infestation.
[60 FR 20402, Apr. 26, 1995, as amended at 62 FR 8371, Feb. 25, 1997]
H. Res. 562 

In the House of Representatives, U. S., 

October 11, 2017. 

Resolved, That upon adoption of this resolution it shall 

be in order to consider in the House the bill (S. 585) to provide greater whistleblower protections for Federal employees, 

increased awareness of Federal whistleblower protections, and 

increased accountability and required discipline for Federal 

supervisors who retaliate against whistleblowers, and for 

other purposes. All points of order against consideration of 

the bill are waived. The bill shall be considered as read. All 

points of order against provisions in the bill are waived. The 

previous question shall be considered as ordered on the bill 

and on any amendment thereto to final passage without intervening motion except: (1) one hour of debate equally divided and controlled by the chair and ranking minority member of the Committee on Oversight and Government Reform; 

and (2) one motion to recommit. 

SEC. 2. On any legislative day during the period from 

October 16, 2017, through October 20, 2017— 
2 

•HRES 562 EH 

(a) the Journal of the proceedings of the previous day 

shall be considered as approved; and 

(b) the Chair may at any time declare the House adjourned to meet at a date and time, within the limits of 

clause 4, section 5, article I of the Constitution, to be announced by the Chair in declaring the adjournment. 

SEC. 3. The Speaker may appoint Members to perform 

the duties of the Chair for the duration of the period addressed by section 2 of this resolution as though under clause 

8(a) of rule I. 

SEC. 4. It shall be in order at any time on the legislative 

day of October 12, 2017, or October 13, 2017, for the Speaker to entertain motions that the House suspend the rules as 

though under clause 1 of rule XV. The Speaker or his designee shall consult with the Minority Leader or her designee 

on the designation of any matter for consideration pursuant 

to this section. 

Attest: 

Clerk.
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
QUARTERLY REPORT 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000813807
<NAME> COURTYARD BY MARRIOTT LIMITED PARTNERSHIP
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLAR
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-28-1997
<EXCHANGE-RATE>                                   1.00
<CASH>                                          35,000
<SECURITIES>                                         0
<RECEIVABLES>                                    8,370
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                21,481
<PP&E>                                         511,496
<DEPRECIATION>                               (212,157)
<TOTAL-ASSETS>                                 364,190
<CURRENT-LIABILITIES>                           27,150
<BONDS>                                        338,137
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     (1,097)
<TOTAL-LIABILITY-AND-EQUITY>                   364,190
<SALES>                                              0
<TOTAL-REVENUES>                                21,688
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                10,227
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               5,580
<INCOME-PRETAX>                                  5,881
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                 12,473
<CHANGES>                                            0
<NET-INCOME>                                    18,354
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        


</TABLE>
---

EXHIBIT 32.2

|CERTIFICATION PURSUANT TO                           
|----------------------------------------------------
|18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
      TO
|SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002       

In connection with the Annual Report of IAS ENERGY,
  Inc. (the "Company") on Form 10-KSB for the period ending April 30, 2007 as
  filed with the Securities and Exchange Commission on the date hereof (the "Report"),
  I, James Vandeberg, Chief Financial Officer of the Company, certify, pursuant
  to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley
  Act of 2002, that:

| | 1. | I have reviewed the Report;                                                                                                                                                                                                                                                                                                                 
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |    |                                                                                                                                                                                                                                                                                                                                             
| | 2. | based on my knowledge, the Report does
        not contain any untrue statement of a material fact or omit to state a
        material fact necessary to make the statements made, in light of the circumstances
        under which such statements were made, not misleading with respect to
        the period covered by the Report; and
| |    |                                                                                                                                                                                                                                                                                                                                             
| | 3. | based on my knowledge, the financial
        statements, and other financial information included in the Report, fairly
        present in all material respects the financial condition, results of operations,
        and cash flows of the registrant as of, and for, the periods presented
        in the Report.                      

|August 9, 2007                           | 
|---------------------------------------- | 
|                                         | 
|/s/
      James Vandeberg                | 
|James Vandeberg, Chief Financial Officer | 
|(Principal Financial Officer)            | 

---
<PAGE>

                                                                      EXHIBIT 99


                                ORTHOMETRIX, INC.
                                -----------------
                          FORM 10-KSB DECEMBER 31, 2002
                          -----------------------------

                            CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Annual Report of Orthometrix, Inc., (the
"Company"), on Form 10-KSB for the year ended December 31, 2002, as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned, in the capacities and on the date indicated below, hereby certifies
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to his knowledge: (1) the Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities and Exchange
Act of 1934; and (2) the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the
Company.



Date: March 31, 2003                   /s/ Reynald Bonmati
                                       -------------------
                                       Reynald Bonmati
                                       Chief Executive Officer




Date:  March 31, 2003
                                       /s/ Neil H. Koenig
                                       ------------------
                                       Neil H. Koenig
                                       Chief Financial Officer
§ 349.55 Labeling of ophthalmic astringent drug products. ( a ) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as an “astringent” (select one of the following: “eye” or “ophthalmic”) “(insert dosage form, e.g., drops).”
( b ) *Indications.* The labeling of the product states, under the heading “Indications,” the following phrase: “For the temporary relief of discomfort from minor eye irritations.”
( c ) *Warnings.* In addition to the warnings in § 349.50, the labeling of the product contains the following warnings under the heading “Warnings” for products containing any ingredient identified in § 349.10: ( 1 ) “If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.”
( 2 ) “If solution changes color or becomes cloudy, do not use.”
( d ) *Directions.* The labeling of the product contains the following information under the heading “Directions”: Instill 1 to 2 drops in the affected eye(s) up to four times daily.
<PAGE>   1

                                                                      EXHIBIT 18



June 6, 1997


Airways Corporation
Orlando, Florida

Ladies and Gentlemen:

We have audited the consolidated balance sheets of Airways Corporation and
subsidiary (the "Company") as of March 31, 1997 and 1996 and the related
consolidated statements of operations, changes in stockholders' equity and
group equity, and cash flows for each of the years then ended and have reported
thereon under date of June 6, 1997.  The aforementioned consolidated financial
statements and our audit report thereon are included in the Company's annual
report on Form 10-K for the year ended March 31, 1997.  As stated in Note (11)
to those financial statements, the Company changed its method of accounting for
Computer Reservation System ("CRS") fee expense and states that the newly
adopted accounting principle is preferable in the circumstances because CRS fee
expense is more appropriately matched with the related revenue and the
treatment of such costs is consistent with the Company's standard revenue
recognition policies.  In accordance with your request, we have reviewed and
discussed with Company officials the circumstances and business judgment and
planning upon which the decision to make this change in the method of
accounting was based.

With regard to the aforementioned accounting change, authoritative criteria
have not been established for evaluating the preferability of one acceptable
method of accounting over another acceptable method.  However, for purposes of
Airways Corporation and subsidiary's compliance with the requirements of the
Securities and Exchange Commission, we are furnishing this letter.

Based on our review and discussion, with reliance on management's business
judgment and planning, we concur that the newly adopted method of accounting is
preferable in the Company's circumstances.



                                          Very truly yours,

                                          KPMG PEAT MARWICK LLP
§ 203.20 Sales restrictions. Except as provided in § 203.22 or § 203.23, no person may sell, purchase, or trade, or offer to sell, purchase, or trade any prescription drug that was: ( a ) Purchased by a public or private hospital or other health care entity; or
( b ) Donated or supplied at a reduced price to a charitable organization.
§ 520.1044b Gentamicin sulfate pig pump oral solution. ( a ) *Specifications.* Each milliliter of pig pump oral solution contains gentamicin sulfate equivalent to 4.35 milligrams of gentamicin.
( b ) *Sponsor.* See Nos. 000061 and 016592 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.300 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Amount.* Administer 1.15 milliliters of pig pump oral solution (5 milligrams of gentamicin) orally per pig one time.
( 2 ) *Indications for use.* In neonatal swine 1 to 3 days of age for control and treatment of colibacillosis caused by strains of *E. coli* sensitive to gentamicin.
( 3 ) *Limitations.* For use in neonatal swine only. Do not slaughter treated swine for food for at least 14 days following treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[49 FR 572, Jan. 5, 1984, as amended at 52 FR 7832, Mar. 13, 1987; 62 FR 29011, May 29, 1997; 78 FR 17596, Mar. 22, 2013; 81 FR 22523, Apr. 18, 2016; 88 FR 27698, May 3, 2023]
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 97-7402
RICHARD ALLEN PULLY, Plaintiff - Appellant, versus E. MONTGOMERY TUCKER, Chairman of Virginia Parole Board, Defendant - Appellee.Appeal from the United States District Court for the Eastern District of Virginia, at Norfolk. J. Calvitt Clarke, Jr., Senior District Judge. (CA-97-875-2) Submitted: December 11, 1997 Decided: December 31, 1997 Before HALL and WILLIAMS, Circuit Judges, and PHILLIPS, Senior Circuit Judge. Dismissed by unpublished per curiam opinion. Richard Allen Pully, Appellant Pro Se. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Appellant, a Virginia inmate, app eals the district court's order denying relief on his 42 U.S.C. § 1983 (1994) complaint under 28 U.S.C.A. § 1915A (West Supp. 1997). We have reviewed the recordand the district court's opinion and find that this appeal is frivolous. Accordingly, we dismiss the appeal on the reasoning of the district court. Pully v. Tucker , No. CA-97-875-2 (E.D. Va. Sept. 26, 1997). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 8923]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4017]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

RIN 0648-XU68


Mid-Atlantic Fishery Management Council (MAFMC); Public Meetings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic 
andAtmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meeting.

-----------------------------------------------------------------------

SUMMARY: The Mid-Atlantic Fishery Management Council (MAFMC) and the 
New England Fishery Management Council's Joint Spiny Dogfish Committee 
will hold a public meeting.

DATES: The meeting will be held on Tuesday, March 16, 2010, from 8 a.m. 
to noon.

ADDRESSES: The workshop will be held at the Kingsmill Conference 
Center, 1010 Kingsmill Road, Williamsburg, VA 23185; telephone: (800) 
832-5665.
    Council address: Mid-Atlantic Fishery Management Council, 800 N. 
State St., Suite 201, Dover, DE 19901; telephone: (302) 674-2331.

FOR FURTHER INFORMATION CONTACT: Daniel T. Furlong, Executive Director, 
Mid-Atlantic Fishery Management Council; telephone: (302) 674-2331.

SUPPLEMENTARY INFORMATION: The purpose of the meeting is to consider 
the provisional MAFMC quota recommendation from its December meeting. A 
review of that recommendation is necessary in light of updates to spiny 
dogfish stock status that occurred through the recent Transboundary 
Resource Assessment Committee (TRAC) review.
    Although non-emergency issues not contained in this agenda may come 
before this group for discussion, in accordance with the Magnuson-
Stevens Fishery Conservation and Management Act (Magnuson-Stevens Act), 
those issues may not be the subject of formal action during this 
meeting. Actions will be restricted to those issues specifically 
identified in this notice and any issues arising after publication of 
this notice that require emergency action under Section 305(c) of the 
Magnuson-Stevens Act, provided the public has been notified of the 
Council's intent to take final action to address the emergency.

Special Accommodations

    This meeting is physically accessible to people with disabilities. 
Requests for sign language interpretation or other auxiliary aid should 
be directed to M. Jan Bryan, (302) 674-2331, at least 5 days prior to 
the meeting date.

    Dated: February 23, 2010.
Tracey L. Thompson,
Acting Director, Office of Sustainable Fisheries, National Marine 
Fisheries Service.
[FR Doc. 2010-4017 Filed 2-25-10; 8:45 am]
BILLING CODE 3510-22-S
§ 226.20 Buildings. Buildings in which Type A medicated article(s) are manufactured, processed, packaged, labeled, or held shall be maintained in a clear and orderly manner and shall be of suitable size, construction and location in relation to surroundings to facilitate maintenance and operation for their intended purpose. The building shall: ( a ) Provide adequate space for the orderly placement of equipment and materials used in any of the following operations for which they are employed to minimize risk of mixups between different Type A medicated article(s), their components, packaging, or labeling: ( 1 ) The receipt, sampling, control, and storage of components.
( 2 ) Manufacturing and processing operations performed on the Type A medicated article(s).
( 3 ) Packaging and labeling operations.
( 4 ) Storage of containers, packaging materials, labeling, and finished products.
( 5 ) Control laboratory operations.
( b ) Provide adequate lighting and ventilation, and when necessary for the intended production or control purposes, adequate screening, dust and temperature controls, to avoid contamination of Type A medicated article(s), and to avoid other conditions unfavorable to the safety, identity, strength, quality, and purity of the raw materials and Type A medicated article(s) before, during, and after production.
( c ) Provide for adequate washing, cleaning, toilet, and locker facilities.
Work areas and equipment used for the production of Type A medicated article(s) or for the storage of the components of Type A medicated article(s) shall not be used for the production, mixing or storage of finished or unfinished insecticides, fungicides, rodenticides, or other pesticides or their components unless such materials are recognized as approved drugs intended for use in animal feeds.
[No. 21520-9-II.

Division Two.

December 12, 1997.]

#### The State of Washington, *Respondent,*v. Alphonze Paul Bassett, *Appellant.*

Appeal from a judgment of the Superior Court for Pierce County, No. 96-1-00419-9, Waldo F. Stone, J., entered December 4, 1996. *Reversed*by unpublished opinion per Bridgewater, J., concurred in by Houghton, C.J., and Seinfeld, J.